Cargando…

Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer

BACKGROUND: Surveillance programmes for women at increased genetic risk of breast cancer are being established worldwide but little is known of their efficacy in early detection of cancers and hence reduction in mortality. METHODS: Data were contributed from seven centres participating in the EU Dem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Møller, Pål, Reis, Marta M., Evans, Gareth, Vasen, Hans, Haites, Neva, Anderson, Elaine, Steel, C. Michael, Apold, Jaran, Lalloo, Fiona, Mæhle, Lovise, Preece, Paul, Gregory, Helen, Heimdal, Ketil, European Familial Breast Cancer Collaborative Group
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 1999
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851417/ https://www.ncbi.nlm.nih.gov/pubmed/10595275 http://dx.doi.org/10.1155/1999/805420

Ejemplares similares

Use of Cytology to Diagnose Inherited Breast Cancer
por: Møller, Pål, et al.
Publicado: (1999)

Germline PTEN mutations are rare and highly penetrant
por: Rustad, Cecilie F, et al.
Publicado: (2006)

Mutation-Specific Survival of Inherited Breast Cancer
por: Møller, P., et al.
Publicado: (1999)

Current Policies for Surveillance and Management in Women at Risk for Breast and Ovarian Cancer: A Survey among 16 European Family Cancer Clinics
por: Vasen, H. F. A., et al.
Publicado: (1999)

No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers
por: Møller, Pål, et al.
Publicado: (2007)

Costs and Benefits of Diagnosing Familial Breast Cancer
por: Heimdal, Ketil, et al.
Publicado: (1999)

Survival in Norwegian BRCA1 mutation carriers with breast cancer
por: Hagen, Anne Irene, et al.
Publicado: (2009)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
por: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Publicado: (2011)

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
por: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Publicado: (2012)

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
por: EBCTCG (Early Breast Cancer Trialists' Collaborative Group)
Publicado: (2014)

High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
por: Møller, Pål, et al.
Publicado: (2010)

BRCA1 1675delA and 1135insA Account for One Third of Norwegian Familial Breast-Ovarian Cancer and Are Associated with Later Disease Onset than Less Frequent Mutations
por: Borg, Åke, et al.
Publicado: (1999)

Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer
por: Møller, P., et al.
Publicado: (1999)

Ethical, Social and Economic Issues in Familial Breast Cancer: A Compilation of Views from the E.C. Biomed II Demonstration Project
por: Steel, Michael, et al.
Publicado: (1999)

Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies
por: Collaborative Group on Epidemiological Studies of Ovarian Cancer
Publicado: (2015)

Complete Mutation Screening and Haplotype Characterization of the BRCA1 Gene in 61 Familial Breast Cancer Patients from Norway
por: Frost, Petter, et al.
Publicado: (2005)

BRCA1 and BRCA2 mutation spectrum – an update on mutation distribution in a large cancer genetics clinic in Norway
por: Heramb, Cecilie, et al.
Publicado: (2018)

Editorial
por: Haites, Neva, et al.
Publicado: (1999)

Differences in Management of Older Women Influence Breast Cancer Survival: Results from a Population-Based Database in Sweden
por: Eaker, Sonja, et al.
Publicado: (2006)

Audit of Women Attending the Aberdeen Genetic Clinic with a Family History of Breast Cancer who Subsequently Develop Cancer
por: Gregory, Helen, et al.
Publicado: (1999)

Utilisation of Prophylactic Mastectomy in 10 European Centres
por: Evans, D. G. R., et al.
Publicado: (1999)

Ten modifiers of BRCA1 penetrance validated in a Norwegian series
por: Heramb, Cecilie, et al.
Publicado: (2015)

The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations
por: Rudkin, Teresa M, et al.
Publicado: (2006)

The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation
por: Møller, Pål, et al.
Publicado: (2014)

Uptake of Genetic Testing and Pre-Test Levels of Mental Distress in Norwegian Families with Known BRCA1 Mutations
por: Reichelt, Jon G., et al.
Publicado: (1999)

Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway
por: Levin, Trine, et al.
Publicado: (2016)

Risk Estimation as a Decision-Making Tool for Genetic Analysis of the Breast Cancer Susceptibility Genes
por: Chang-Claude, Jenny, et al.
Publicado: (1999)

Haplotype Analysis of Norwegian and Swedish Patients with Acute Intermittent Porphyria (AIP): Extreme Haplotype Heterogeneity for the Mutation R116W
por: Tjensvoll, Kjersti, et al.
Publicado: (2003)

Screening for germline rearrangements in BRCA1 and BRCA2 in Norwegian families with breast or breast/ovarian cancer
por: Van Ghelue, M, et al.
Publicado: (2005)

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial
por: FOxTROT Collaborative Group
Publicado: (2012)

The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry
por: Grindedal, Eli Marie, et al.
Publicado: (2014)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial
por: Heart Protection Study Collaborative Group
Publicado: (2011)

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study
por: Heart Protection Study Collaborative Group
Publicado: (2011)

Cancer Genetics Services in Europe
por: Hodgson, S., et al.
Publicado: (1999)

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
por: Landray, M.J., et al.
Publicado: (2017)

Genetic Testing for Breast Cancer Predisposition in 1999: Which Molecular Strategy and which Family Criteria?
por: Stoppa-Lyonnet, D., et al.
Publicado: (1999)

Diagnostic mRNA splicing assay for variants in BRCA1 and BRCA2 identified two novel pathogenic splicing aberrations
por: Wangensteen, Teresia, et al.
Publicado: (2019)

Insurance Implications for Individuals with a High Risk of Breast and Ovarian Cancer in Europe
por: Morrison, P. J., et al.
Publicado: (1999)

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
por: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group
Publicado: (2010)

BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer
por: Norum, Jan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d508hkkffh5h0ge35jlth37o2a